HeartSciences Secures European Patent for AI-Driven ECG Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Source: Newsfilter
- Patent Grant: HeartSciences has been awarded European Patent No. EP4252651 by the EPO, covering ECG-based assessment of diastolic function, marking a significant expansion of its AI-ECG intellectual property portfolio and is expected to enhance its competitive edge in the market.
- Technological Innovation: The patented technology employs machine learning models to compute echocardiogram parameters indicative of diastolic function directly from ECG data and patient demographics, significantly improving the efficiency and accuracy of cardiac disease screening.
- Market Coverage: The patent took effect on April 29, 2026, providing coverage in 19 European countries, including Germany, France, and Italy, thereby reinforcing HeartSciences' strategic positioning in the European market.
- Intellectual Property Value: With over 45 granted patents, HeartSciences demonstrates a robust technological foundation and commercial advantage in the AI-ECG field, which is expected to support the company's future financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSCS
Wall Street analysts forecast HSCS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.820
Low
9.20
Averages
10.60
High
12.00
Current: 1.820
Low
9.20
Averages
10.60
High
12.00
No data
About HSCS
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HeartSciences Secures European Patent for AI-Driven ECG Technology
- Patent Grant: HeartSciences has been awarded European Patent No. EP4252651 by the EPO, covering ECG-based assessment of diastolic function, marking a significant expansion of its AI-ECG intellectual property portfolio and is expected to enhance its competitive edge in the market.
- Technological Innovation: The patented technology employs machine learning models to compute echocardiogram parameters indicative of diastolic function directly from ECG data and patient demographics, significantly improving the efficiency and accuracy of cardiac disease screening.
- Market Coverage: The patent took effect on April 29, 2026, providing coverage in 19 European countries, including Germany, France, and Italy, thereby reinforcing HeartSciences' strategic positioning in the European market.
- Intellectual Property Value: With over 45 granted patents, HeartSciences demonstrates a robust technological foundation and commercial advantage in the AI-ECG field, which is expected to support the company's future financial performance.
See More
HeartSciences Launches AI-ECG Algorithm Marketplace with FDA-Cleared Model
- Platform Update Released: HeartSciences announced the commercial release of MyoVista Insights™ version 1.3, introducing the AI-ECG Algorithm Marketplace, which allows integration of third-party algorithms, marking a significant advancement in ECG technology.
- FDA-Cleared Algorithm: The Bunkerhill Health ECG-EF model, which is FDA-cleared, enables clinicians to detect reduced left ventricular ejection fraction (LVEF ≤40%) from a routine 12-lead ECG, providing earlier identification of heart failure risk.
- Innovative Revenue Model: The marketplace offers a SaaS-based revenue model for AI-ECG developers, reducing the complexity of entering the clinical market, and is expected to attract more algorithm developers, driving sustainable revenue growth for the company.
- Medical Reimbursement Support: Assessments using AI-ECG algorithms are eligible for approximately $136 in Medicare reimbursement in 2026, and with the multi-billion-dollar market forecast for AI-ECG, HeartSciences is positioned for significant revenue growth in the future.
See More
HeartSciences Achieves Epic Toolbox Designation for MyoVista Insights
- Platform Certification: HeartSciences' MyoVista Insights™ platform has received Epic Toolbox designation, marking a significant milestone in the ECG management system sector and enhancing the company's competitiveness in the healthcare IT market.
- Integration Capabilities: The platform supports integration with hospital information systems and electronic health records (EHRs) using HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR, ensuring clinicians can seamlessly access MyoVista Insights™ within existing workflows.
- Clinical Decision Support: MyoVista Insights™ is designed to enhance workflow efficiency and support clinical decision-making, which is expected to improve healthcare providers' workflows, thereby enhancing patient care quality and efficiency.
- Strategic Expansion: CEO Andrew Simpson stated that this certification is a crucial part of the company's interoperability strategy aimed at expanding access to MyoVista Insights™ across healthcare systems, driving future market growth.
See More
Heart Test Laboratories Q3 Earnings Beat Expectations
- Earnings Surprise: Heart Test Laboratories reported a Q3 GAAP EPS of -$0.63, beating market expectations by $0.19, indicating the company's resilience in challenging conditions.
- Cash Position: The company holds $3.4 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operational and investment needs.
- Shareholder Equity Insight: With shareholders' equity at $2.7 million, the company shows stability in its capital structure, maintaining a healthy balance sheet despite ongoing profitability challenges.
- Market Reaction Outlook: Following the earnings release, market interest in Heart Test Laboratories may increase, with investors closely monitoring its future financial performance and strategic direction.
See More
HeartSciences Partners with Cibolo Health for ECG Management
- Partnership Agreement: HeartSciences has partnered with Cibolo Rural Health Networks, selecting MyoVista Insights™ as the endorsed ECG management platform for 123 independent hospitals, enhancing healthcare quality and efficiency.
- Technology Integration: With MyoVista Insights, Cibolo Health's hospitals will modernize ECG workflows, enabling physicians to interpret ECGs more quickly and efficiently, thereby improving clinical decision-making processes.
- Cloud Platform Advantages: MyoVista Insights offers secure cloud-based ECG data management, supporting various devices and file formats, ensuring regulatory-compliant AI-ECG algorithms can be integrated into routine clinical practice, enhancing accessibility to healthcare services.
- Strategic Implications: This collaboration aligns with Cibolo Health's mission to optimize care delivery while also driving HeartSciences' market expansion within high-value networks, strengthening its competitive position in the healthcare information technology sector.
See More
HeartSciences Submits MyoVista Device to FDA, Advancing AI ECG Technology
- Product Advancement: HeartSciences submitted its MyoVista® wavECG™ device to the FDA for 510(k) clearance at the end of its fiscal second quarter on October 31, 2025, marking a significant regulatory milestone that is expected to accelerate the product's market entry.
- Software Platform Validation: Since its launch in May 2025, the MyoVista Insights™ platform has received strong validation from early adopters and is currently engaged in commercial discussions with several healthcare institutions, with multiple key customer wins expected to be announced soon, further driving revenue growth.
- Market Opportunity: As a Medical Device Data System, MyoVista Insights carries significantly lower regulatory requirements, which is anticipated to substantially reduce the costs and speed of commercial rollout, enabling the company to quickly tap into a multibillion-dollar market opportunity.
- Financial Position: As of October 31, 2025, HeartSciences reported approximately $2.0 million in cash and cash equivalents and $4.2 million in shareholders' equity, and while no meaningful revenue was generated in FQ2 2026, the company is actively advancing its commercialization strategy.
See More
HeartSciences Secures European Patent for AI-Driven ECG Technology
- Patent Grant: HeartSciences has been awarded European Patent No. EP4252651 by the EPO, covering ECG-based assessment of diastolic function, marking a significant expansion of its AI-ECG intellectual property portfolio and is expected to enhance its competitive edge in the market.
- Technological Innovation: The patented technology employs machine learning models to compute echocardiogram parameters indicative of diastolic function directly from ECG data and patient demographics, significantly improving the efficiency and accuracy of cardiac disease screening.
- Market Coverage: The patent took effect on April 29, 2026, providing coverage in 19 European countries, including Germany, France, and Italy, thereby reinforcing HeartSciences' strategic positioning in the European market.
- Intellectual Property Value: With over 45 granted patents, HeartSciences demonstrates a robust technological foundation and commercial advantage in the AI-ECG field, which is expected to support the company's future financial performance.
See More
HeartSciences Launches AI-ECG Algorithm Marketplace with FDA-Cleared Model
- Platform Update Released: HeartSciences announced the commercial release of MyoVista Insights™ version 1.3, introducing the AI-ECG Algorithm Marketplace, which allows integration of third-party algorithms, marking a significant advancement in ECG technology.
- FDA-Cleared Algorithm: The Bunkerhill Health ECG-EF model, which is FDA-cleared, enables clinicians to detect reduced left ventricular ejection fraction (LVEF ≤40%) from a routine 12-lead ECG, providing earlier identification of heart failure risk.
- Innovative Revenue Model: The marketplace offers a SaaS-based revenue model for AI-ECG developers, reducing the complexity of entering the clinical market, and is expected to attract more algorithm developers, driving sustainable revenue growth for the company.
- Medical Reimbursement Support: Assessments using AI-ECG algorithms are eligible for approximately $136 in Medicare reimbursement in 2026, and with the multi-billion-dollar market forecast for AI-ECG, HeartSciences is positioned for significant revenue growth in the future.
See More
HeartSciences Achieves Epic Toolbox Designation for MyoVista Insights
- Platform Certification: HeartSciences' MyoVista Insights™ platform has received Epic Toolbox designation, marking a significant milestone in the ECG management system sector and enhancing the company's competitiveness in the healthcare IT market.
- Integration Capabilities: The platform supports integration with hospital information systems and electronic health records (EHRs) using HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR, ensuring clinicians can seamlessly access MyoVista Insights™ within existing workflows.
- Clinical Decision Support: MyoVista Insights™ is designed to enhance workflow efficiency and support clinical decision-making, which is expected to improve healthcare providers' workflows, thereby enhancing patient care quality and efficiency.
- Strategic Expansion: CEO Andrew Simpson stated that this certification is a crucial part of the company's interoperability strategy aimed at expanding access to MyoVista Insights™ across healthcare systems, driving future market growth.
See More
Heart Test Laboratories Q3 Earnings Beat Expectations
- Earnings Surprise: Heart Test Laboratories reported a Q3 GAAP EPS of -$0.63, beating market expectations by $0.19, indicating the company's resilience in challenging conditions.
- Cash Position: The company holds $3.4 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operational and investment needs.
- Shareholder Equity Insight: With shareholders' equity at $2.7 million, the company shows stability in its capital structure, maintaining a healthy balance sheet despite ongoing profitability challenges.
- Market Reaction Outlook: Following the earnings release, market interest in Heart Test Laboratories may increase, with investors closely monitoring its future financial performance and strategic direction.
See More
HeartSciences Partners with Cibolo Health for ECG Management
- Partnership Agreement: HeartSciences has partnered with Cibolo Rural Health Networks, selecting MyoVista Insights™ as the endorsed ECG management platform for 123 independent hospitals, enhancing healthcare quality and efficiency.
- Technology Integration: With MyoVista Insights, Cibolo Health's hospitals will modernize ECG workflows, enabling physicians to interpret ECGs more quickly and efficiently, thereby improving clinical decision-making processes.
- Cloud Platform Advantages: MyoVista Insights offers secure cloud-based ECG data management, supporting various devices and file formats, ensuring regulatory-compliant AI-ECG algorithms can be integrated into routine clinical practice, enhancing accessibility to healthcare services.
- Strategic Implications: This collaboration aligns with Cibolo Health's mission to optimize care delivery while also driving HeartSciences' market expansion within high-value networks, strengthening its competitive position in the healthcare information technology sector.
See More
HeartSciences Submits MyoVista Device to FDA, Advancing AI ECG Technology
- Product Advancement: HeartSciences submitted its MyoVista® wavECG™ device to the FDA for 510(k) clearance at the end of its fiscal second quarter on October 31, 2025, marking a significant regulatory milestone that is expected to accelerate the product's market entry.
- Software Platform Validation: Since its launch in May 2025, the MyoVista Insights™ platform has received strong validation from early adopters and is currently engaged in commercial discussions with several healthcare institutions, with multiple key customer wins expected to be announced soon, further driving revenue growth.
- Market Opportunity: As a Medical Device Data System, MyoVista Insights carries significantly lower regulatory requirements, which is anticipated to substantially reduce the costs and speed of commercial rollout, enabling the company to quickly tap into a multibillion-dollar market opportunity.
- Financial Position: As of October 31, 2025, HeartSciences reported approximately $2.0 million in cash and cash equivalents and $4.2 million in shareholders' equity, and while no meaningful revenue was generated in FQ2 2026, the company is actively advancing its commercialization strategy.
See More
